Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of AK146D1 combined with AK112 or other antitumor therapy in advanced non-small cell lung cancer
CTR20262393Phase 2Active
- Sponsor
- Akeso, Inc.
- Start
- Jul 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of AK146D1, ivonescimab in non-small cell lung cancer (NSCLC), sponsored by Akeso, Inc.. Started Jul 2026; status: active.
02
Drugs
AK146D1ivonescimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20262393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262393.